Organon & Co
NYSE : OGNFinancials
Balance sheet · full history
USD in millions · per-share amounts unscaled. Each period shows the value from the latest filing that prints it.
| Reported line item | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 12 | 737 | 706 | 693 | 675 | 574 |
| Accounts receivable (net of allowance for doubtful accounts of $12 in 2025 and $14 in 2024) | 1,038 | 1,382 | 1,475 | 1,744 | 1,358 | 1,331 |
| Inventories (excludes inventories of $236 in 2025 and $215 in 2024 classified in Other assets) | 913 | 915 | 1,003 | 1,315 | 1,321 | 1,406 |
| Other current assets | 930 | 726 | 747 | 756 | 994 | 1,033 |
| Assets held for sale | 0 | 8 | ||||
| Current assets of discontinued operationsno longer reported | 674 | 0 | ||||
| Total Current Assets | 3,567 | 3,760 | 3,931 | 4,508 | 4,348 | 4,352 |
| Property, plant and equipment, net | 984 | 973 | 1,018 | 1,183 | 1,168 | 1,303 |
| Goodwill | 4,603 | 4,603 | 4,603 | 4,603 | 4,680 | 4,153 |
| Intangibles, net | 503 | 651 | 649 | 533 | 1,414 | 1,130 |
| Other assets | 361 | 694 | 754 | 1,231 | 1,491 | 1,539 |
| Noncurrent assets held for sale | 0 | 390 | ||||
| Noncurrent assets of discontinued operationsno longer reported | 91 | 0 | ||||
| Total Assets | 10,109 | 10,681 | 10,955 | 12,058 | 13,101 | 12,867 |
| Current portion of long-term debt and short-term borrowings | 20 | 16 | ||||
| Current portion of long-term debtno longer reported | 0 | 9 | 8 | 9 | 20 | |
| Trade accounts payable | 259 | 1,382 | 1,132 | 1,314 | 1,153 | 952 |
| Accrued and other current liabilities | 659 | 1,021 | 1,188 | 1,389 | 1,411 | 1,335 |
| Income taxes payable | 288 | 185 | 184 | 206 | 134 | 85 |
| Due to related partyno longer reported | 1,339 | 0 | ||||
| Liabilities held for sale | 0 | 2 | ||||
| Current liabilities of discontinued operationsno longer reported | 128 | 0 | ||||
| Total Current Liabilities | 2,673 | 2,597 | 2,512 | 2,918 | 2,718 | 2,390 |
| Long-term debt | 0 | 9,125 | 8,905 | 8,751 | 8,860 | 8,628 |
| Deferred income taxes | 128 | 4 | 19 | 47 | 74 | 57 |
| Other noncurrent liabilities | 1,739 | 463 | 411 | 412 | 977 | 1,008 |
| Noncurrent liabilities held for sale | 0 | 32 | ||||
| Noncurrent liabilities of discontinued operationsno longer reported | 83 | 0 | ||||
| Total Liabilities | 11,847 | 12,128 | 12,629 | 12,115 | ||
| Contingencies (Note 18) | — | — | — | — | — | — |
| Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 260,316 in 2025 and 257,799 in 2024 | 0 | 3 | 3 | 3 | 3 | 3 |
| Additional paid-in capital | 0 | 25 | 108 | 167 | ||
| Additional paid-in capitalno longer reported | 0 | 0 | ||||
| Retained earnings | 0 | (998) | (331) | 443 | 1,010 | 1,109 |
| Accumulated other comprehensive loss | (622) | (513) | (564) | (541) | (649) | (527) |
| Net investment from Merck & Co., Inc.no longer reported | 6,108 | 0 | ||||
| Total Stockholders Equity | 5,486 | (1,508) | (892) | (70) | 472 | 752 |
| Total Liabilities and Stockholders Equity | 10,109 | 10,681 | 10,955 | 12,058 | 13,101 | 12,867 |
History starts FY2020, the period ended Dec 31, 2020 — the earliest period our structured-data source covers, not the company’s first year.
38 reported lines · 6 periods · values taken from the latest filing that prints each period.
- italic8 from an earlier filing than the rest of the column.
- no longer reported8 lines the filer stopped printing.
- — the filer printed the line and left the period empty. An empty cell means the line was not printed at all; it is never a zero.
169 of 169 values link to the exact element in the filer’s own document.
Every line and every caption is the company’s own. Each period carries the value from the latest filing that prints it, which is why a restated period shows the restated number with the figure as first reported kept underneath.
Nothing on this table is computed by us: no fourth quarter, no growth rate, no margin. Marks describe the filer’s own restatements.